In conclusion, sitagliptin use was associated with an increased risk of HHF inpatients with T2DM receiving dialysis, especially in those without severehypoglycemia, without ACE inhibitors treatment, with prior heart failure orreceiving hemodialysis. The gene discussed is ACE; the disease is heart failure.